Berdazimer is a nitric oxide (NO)-releasing agent used to treat topical molluscum contagiosum. Berdazimer is a polymeric substance consisting of a polysiloxane backbone (Si-O-Si bonds) with covalently bound N-diazeniumdiolate nitric oxide (NO) donors.
- Mechanism
- Curator reviewed · 3 references
Although the mechanism of action in treating molluscum contagiosum is unknown, berdazimer is known to be a nitric oxide (NO)-releasing agent from the N-diazeniumdiolate nitric oxide donors. NO has been known to have broad-spectrum antimicrobial and antiviral activity, likely due to the S-nitrosylation of proteins and cytotoxicity to viral replication from reactive oxygen species.
- Primary indication
- Berdazimer is indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older.Curator reviewed · 1 structured indication
- First approval
- United States, 2025
- Also known as
- Silsesquioxanes, 3-(2-hydroxy-1-methyl-2-nitrosohydrazinyl)propyl 3-(methylamino)propyl, polymers with silicic acid (h4sio4) tetra-et ester, hydroxy-terminated
- Code names
- NVN-1000 free acid
- Brand names
Resolves to
What you can answer from here — as of September 12, 2026
Which other approved drugs treat the same conditions as Berdazimer, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account